View Item 

Show simple item record

Future large‐scale clinical trials in cardiovascular medicine: challenges and uncertainties
dc.contributor.authorPacker, Milton
dc.contributor.authorPitt, Bertram
dc.date.accessioned2019-01-15T20:24:50Z
dc.date.available2020-02-03T20:18:24Zen
dc.date.issued2018-12
dc.identifier.citationPacker, Milton; Pitt, Bertram (2018). "Future large‐scale clinical trials in cardiovascular medicine: challenges and uncertainties." European Journal of Heart Failure 20(12): 1645-1648.
dc.identifier.issn1388-9842
dc.identifier.issn1879-0844
dc.identifier.urihttps://hdl.handle.net/2027.42/146871
dc.publisherJohn Wiley & Sons, Ltd
dc.titleFuture large‐scale clinical trials in cardiovascular medicine: challenges and uncertainties
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelCardiovascular Medicine
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146871/1/ejhf1360_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/146871/2/ejhf1360.pdf
dc.identifier.doi10.1002/ejhf.1360
dc.identifier.sourceEuropean Journal of Heart Failure
dc.identifier.citedreferencePacker M. The imminent demise of cardiovascular drug development. JAMA Cardiol 2017; 2: 1293 – 1294.
dc.identifier.citedreferencePacker M. Angiotensin neprilysin inhibition for patients with heart failure: what if sacubitril/valsartan were a treatment for cancer? JAMA Cardiol 2016; 1: 971 – 972.
dc.identifier.citedreferenceTran G, Zafar SY. Financial toxicity and implications for cancer care in the era of molecular and immune therapies. Ann Transl Med 2018; 6: 166.
dc.identifier.citedreferencePfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O’Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial. Circulation 2015; 131: 34 – 42.
dc.identifier.citedreferenceAgarwal R. Implications of blood pressure measurement technique for implementation of Systolic Blood Pressure Intervention Trial (SPRINT). J Am Heart Assoc 2017; 6:e004536.
dc.identifier.citedreferenceCorreia LC, Correia VC, Souza TM, Cerqueira AM Jr, Alexandre FK, Garcia G, Ferreira FR, Lopes FO. Inconsistency prevents the valuable synergism of explanatory and pragmatic trails. J Evid Based Med 2018; 11: 105 – 111.
dc.identifier.citedreferenceDal‐Ré R, Janiaud P, Ioannidis JP. Real‐world evidence: how pragmatic are randomized controlled trials labeled as pragmatic? BMC Med 2018; 16: 49.
dc.identifier.citedreferenceSchwartz D, Lellouch J. Explanatory and pragmatic attitudes in therapeutical trials. J Chronic Dis 1967; 20: 637 – 648.
dc.identifier.citedreferenceToRsemide compArisoN With furoSemide FORManagement of Heart Failure (TRANSFORM‐HF). ClinicalTrials.gov Identifier: NCT03296813. https://clinicaltrials.gov/ct2/show/NCT03296813?term=NCT03296813&rank=1 (29 October 2018).
dc.identifier.citedreferenceSpironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction (SPIRRIT). ClinicalTrials.gov Identifier: NCT02901184. https://clinicaltrials.gov/ct2/show/NCT02901184?term=NCT02901184&rank=1 (29 October 2018).
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
ejhf1360_am.pdf
Size:
246.8KB
Format:
PDF
View/Open
Name:
ejhf1360.pdf
Size:
69.62KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.